| Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19 MJ Levin, A Ustianowski, S De Wit, O Launay, M Avila, A Templeton, ... New England Journal of Medicine 386 (23), 2188-2200, 2022 | 641 | 2022 |
| A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation P Peretti-Watel, V Seror, S Cortaredona, O Launay, J Raude, P Verger, ... The Lancet infectious diseases 20 (7), 769-770, 2020 | 591 | 2020 |
| Tuberculosis in HIV-infected patients: a comprehensive review L Aaron, D Saadoun, I Calatroni, O Launay, N Memain, V Vincent, ... Clinical microbiology and infection 10 (5), 388-398, 2004 | 538 | 2004 |
| Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial JL Bresson, C Perronne, O Launay, C Gerdil, M Saville, J Wood, ... The Lancet 367 (9523), 1657-1664, 2006 | 505 | 2006 |
| Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study F Dromer, S Mathoulin-Pélissier, O Launay, O Lortholary, ... PLoS medicine 4 (2), e21, 2007 | 460 | 2007 |
| The French public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue JK Ward, C Alleaume, P Peretti-Watel, V Seror, S Cortaredona, O Launay, ... Social science & medicine 265, 113414, 2020 | 425 | 2020 |
| Vaccine hesitancy among general practitioners and its determinants during controversies: a national cross-sectional survey in France P Verger, L Fressard, F Collange, A Gautier, C Jestin, O Launay, J Raude, ... EBioMedicine 2 (8), 891-897, 2015 | 374 | 2015 |
| Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled … F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ... The Lancet infectious diseases 22 (2), 209-221, 2022 | 356 | 2022 |
| No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception L Mandelbrot, R Tubiana, J Le Chenadec, C Dollfus, A Faye, E Pannier, ... Clinical Infectious Diseases 61 (11), 1715-1725, 2015 | 355 | 2015 |
| Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness AR Falsey, JE McElhaney, J Beran, GA Van Essen, X Duval, M Esen, ... The Journal of infectious diseases 209 (12), 1873-1881, 2014 | 259 | 2014 |
| Mucosal imprinting of vaccine-induced CD8+ T cells is crucial to inhibit the growth of mucosal tumors F Sandoval, M Terme, M Nizard, C Badoual, MF Bureau, L Freyburger, ... Science translational medicine 5 (172), 172ra20-172ra20, 2013 | 236 | 2013 |
| Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial O Launay, D van der Vliet, AR Rosenberg, ML Michel, L Piroth, D Rey, ... Jama 305 (14), 1432-1440, 2011 | 201 | 2011 |
| Knowledge, attitudes and vaccination coverage of healthcare workers regarding occupational vaccinations P Loulergue, F Moulin, G Vidal-Trecan, Z Absi, C Demontpion, C Menager, ... Vaccine 27 (31), 4240-4243, 2009 | 195 | 2009 |
| Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis S Kernéis, O Launay, C Turbelin, F Batteux, T Hanslik, PY Boëlle Clinical infectious diseases 58 (8), 1130-1139, 2014 | 185 | 2014 |
| Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice D Bouhassira, O Chassany, J Gaillat, T Hanslik, O Launay, C Mann, ... Pain 153 (2), 342-349, 2012 | 184 | 2012 |
| Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients C Charlier, C Henegar, O Launay, C Pagnoux, A Berezne, B Bienvenu, ... Annals of the rheumatic diseases 68 (5), 658-663, 2009 | 175 | 2009 |
| AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial JE McElhaney, J Beran, JM Devaster, M Esen, O Launay, G Leroux-Roels, ... The Lancet infectious diseases 13 (6), 485-496, 2013 | 173 | 2013 |
| Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss E Dam, R Quercia, B Glass, D Descamps, O Launay, X Duval, ... PLoS pathogens 5 (3), e1000345, 2009 | 171 | 2009 |
| Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review S Galmiche, LBL Nguyen, E Tartour, X de Lamballerie, L Wittkop, ... Clinical Microbiology and Infection 28 (2), 163-177, 2022 | 164 | 2022 |
| Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era C Charlier, F Dromer, C Leveque, L Chartier, YS Cordoliani, A Fontanet, ... PloS one 3 (4), e1950, 2008 | 147 | 2008 |
Verger PierreORS PACA在 inserm.fr 的电子邮件经过验证
